Cargando…

Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients

Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleki, Kiarash, Shirzad, Moein, Javanian, Mostafa, Mohammadkhani, Sheyda, Alijani, Mohammad Hossein, Miri, Niloufarsadat, Oladnabi, Morteza, Azadmehr, Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471328/
https://www.ncbi.nlm.nih.gov/pubmed/36119078
http://dx.doi.org/10.3389/fimmu.2022.947401
_version_ 1784789048569626624
author Saleki, Kiarash
Shirzad, Moein
Javanian, Mostafa
Mohammadkhani, Sheyda
Alijani, Mohammad Hossein
Miri, Niloufarsadat
Oladnabi, Morteza
Azadmehr, Abbas
author_facet Saleki, Kiarash
Shirzad, Moein
Javanian, Mostafa
Mohammadkhani, Sheyda
Alijani, Mohammad Hossein
Miri, Niloufarsadat
Oladnabi, Morteza
Azadmehr, Abbas
author_sort Saleki, Kiarash
collection PubMed
description Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients.
format Online
Article
Text
id pubmed-9471328
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94713282022-09-15 Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients Saleki, Kiarash Shirzad, Moein Javanian, Mostafa Mohammadkhani, Sheyda Alijani, Mohammad Hossein Miri, Niloufarsadat Oladnabi, Morteza Azadmehr, Abbas Front Immunol Immunology Finding cytokine storm initiator factors associated with uncontrolled inflammatory immune response is necessary in COVID-19 patients. The aim was the identification of Fas/Fas Ligand (FasL) role in lung involvement and mortality of COVID-19 patients. In this case-control study, mild (outpatient), moderate (hospitalized), and severe (ICU) COVID-19 patients and healthy subjects were investigated. RNA isolated from PBMCs for cDNA synthesis and expression of mFas/mFasL mRNA was evaluated by RT-PCR. Serum sFas/sFasL protein by ELISA and severity of lung involvement by CT-scan were evaluated. Also, we docked Fas and FasL via Bioinformatics software (in silico) to predict the best-fit Fas/FasL complex and performed molecular dynamics simulation (MDS) in hyponatremia and fever (COVID-19 patients), and healthy conditions. mFasL expression was increased in moderate and severe COVID-19 patients compared to the control group. Moreover, mFas expression showed an inverse correlation with myalgia symptom in COVID-19 patients. Elevation of sFasL protein in serum was associated with reduced lung injury and mortality. Bioinformatics analysis confirmed that blood profile alterations of COVID-19 patients, such as fever and hyponatremia could affect Fas/FasL complex interactions. Our translational findings showed that decreased sFasL is associated with lung involvement; severity and mortality in COVID-19 patients. We think that sFasL is a mediator of neutrophilia and lymphopenia in COVID-19. However, additional investigation is suggested. This is the first report describing that the serum sFasL protein is a severity and mortality prognostic marker for the clinical management of COVID-19 patients. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471328/ /pubmed/36119078 http://dx.doi.org/10.3389/fimmu.2022.947401 Text en Copyright © 2022 Saleki, Shirzad, Javanian, Mohammadkhani, Alijani, Miri, Oladnabi and Azadmehr https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Saleki, Kiarash
Shirzad, Moein
Javanian, Mostafa
Mohammadkhani, Sheyda
Alijani, Mohammad Hossein
Miri, Niloufarsadat
Oladnabi, Morteza
Azadmehr, Abbas
Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
title Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
title_full Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
title_fullStr Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
title_full_unstemmed Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
title_short Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
title_sort serum soluble fas ligand is a severity and mortality prognostic marker for covid-19 patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471328/
https://www.ncbi.nlm.nih.gov/pubmed/36119078
http://dx.doi.org/10.3389/fimmu.2022.947401
work_keys_str_mv AT salekikiarash serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT shirzadmoein serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT javanianmostafa serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT mohammadkhanisheyda serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT alijanimohammadhossein serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT miriniloufarsadat serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT oladnabimorteza serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients
AT azadmehrabbas serumsolublefasligandisaseverityandmortalityprognosticmarkerforcovid19patients